Performance of CHA 2 DS 2 -VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer.
Alyaa M AjabnoorSalwa S ZghebiRosa ParisiDarren M AshcroftCorinne Faivre-FinnMamas Andreas MamasEvangelos KontopantelisPublished in: European heart journal open (2024)
-VASc performs similarly in predicting stroke to AF patients without cancer. Our findings highlight the importance of cancer diagnosis during the development of risk scores and opportunities to optimize the HAS-BLED risk score to better serve cancer patients with AF.
Keyphrases
- atrial fibrillation
- papillary thyroid
- squamous cell
- oral anticoagulants
- catheter ablation
- left atrial
- heart failure
- left atrial appendage
- direct oral anticoagulants
- lymph node metastasis
- chronic kidney disease
- newly diagnosed
- prognostic factors
- ejection fraction
- percutaneous coronary intervention
- coronary artery disease
- patient reported outcomes
- blood brain barrier